Cardiac repair by reprogramming of cardiac fibroblasts into cardiomyocytes
US9523079B2 · kind B2 · utility
5Cited by
0References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 28, 2015 |
| Grant date | Dec 20, 2016 |
| Priority date | — |
| Expiry date | Apr 28, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2770/00043
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention involves the use of transcription factors including Tbx5, Mef2C, Hand2, myocardin and Gata4 to reprogram cardiac fibroblasts into cardiomyocytes, both in vitro and in vivo. Such methods find particular use in the treatment of patients post-myocardial infarction to prevent or limit scarring and to promote myocardial repair.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.